Ischemic Heart Disease
📧 Sign up to get email alerts when something new happens for Ischemic Heart Disease.
Sign up freeTop drugs studied for this disease
-
FDA approval · 2022-12-06FDA Approved: MYOVIEW — Supplemental Application (Medi-Physics Inc. dba GE Healthcare)
FDA approved a supplemental application for MYOVIEW (tetrofosmin) submitted by Medi-Physics Inc. dba GE Healthcare.
-
FDA approval · 2022-11-03FDA Approved: AMMONIA N 13 — Original Application (University of Alabama at Birmingham)
FDA approved the original application for Ammonia N-13 (NH3N13), a radiopharmaceutical imaging agent developed by the University of Alabama …
-
FDA approval · 2022-10-26FDA Approved: REGADENOSON — Original Application (Eugia US LLC)
FDA approved Regadenoson via an original application for Eugia US LLC (ANDA216437), enabling a generic version of Regadenoson for pharmacolo…
-
CLINICAL_TRIALS trial_result · 2022-09-28Clinical Trial Update: Chronic Total Occlusion Percutaneous Coronary Intervention Study [NA]
A completed clinical trial studying chronic total occlusion percutaneous coronary intervention in ischemic heart disease conditions.
-
CLINICAL_TRIALS withdrawal · 2022-09-22Clinical Trial Update: Adipose Stromal Cells Injection in the Myocardium for Induction of Revascularization [Phase 3]
Phase 3 trial of adipose stromal cell injection in the myocardium for revascularization was withdrawn.
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
FDA approval · 2022-08-31FDA Approved: REGADENOSON — Original Application (Hospira, Inc.)
FDA approved Hospira's Regadenoson as a generic (ANDA 214349) for use as a pharmacologic stress agent to detect myocardial ischemia in patie…
-
FDA approval · 2022-07-12FDA Approved: REGADENOSON — Original Application (Almaject, Inc.)
The FDA approved Almaject, Inc.'s original Abbreviated New Drug Application for regadenoson, a pharmacologic stress agent used in myocardial…
-
FDA approval · 2022-05-23FDA Approved: REGADENOSON — Original Application (International Medication Systems, Limited)
FDA approved an original ANDA for Regadenoson by International Medication Systems, Limited, authorizing a generic regadenoson product for us…
-
CLINICAL_TRIALS trial_result · 2022-05-19Clinical Trial Update: Mono- Versus Dual antiPlatelet Therapy During 6-12 Months After New Generation Drug Eluting Stent Implantation [Phase 4]
Phase 4 trial comparing mono- versus dual antiplatelet therapy after new-generation drug-eluting stent implantation; completed.
-
FDA approval · 2022-05-17FDA Approved: TECHNETIUM TC 99M SESTAMIBI — Supplemental Application (Curium US LLC)
FDA approved a supplemental application for Technetium Tc-99m Sestamibi, updating its labeling and approved use in diagnostic myocardial per…
-
FDA approval · 2022-04-11FDA Approved: REGADENOSON — Original Application (Apotex Corp.)
FDA approved Apotex Corp.'s generic Regadenoson for use as a pharmacologic stress agent in myocardial perfusion imaging to evaluate for coro…
-
FDA approval · 2022-04-11FDA Approved: REGADENOSON — Original Application (Dr. Reddy's Laboratories Inc.)
FDA approved the original application for Regadenoson from Dr. Reddy's Laboratories Inc. as a generic product for pharmacologic stress testi…
-
FDA approval · 2022-04-11FDA Approved: REGADENOSON — Original Application (Meitheal Pharmaceuticals Inc.)
FDA approved Meitheal Pharmaceuticals' original (ANDA) application for Regadenoson, a generic pharmacologic stress agent used for myocardial…
-
CLINICAL_TRIALS trial_result · 2022-04-04Clinical Trial Update: Ozone Therapy in Refractory Ischemic Heart Disease. [Phase 2, Phase 3]
A clinical trial update for ozone therapy in ischemic heart disease has been terminated after Phase 2/3 testing.
-
FDA approval · 2022-03-09FDA Approved: MYOVIEW — Supplemental Application (Medi-Physics Inc. dba GE Healthcare)
FDA approved a supplemental application for MYOVIEW (tetrofosmin) by Medi-Physics Inc. dba GE Healthcare, authorizing an updated use of the …
-
CLINICAL_TRIALS trial_result · 2022-02-02Clinical Trial Update: Serial Infusions of Allogeneic Mesenchymal Stem Cells in Cardiomyopathy Patients With Left Ventricular Assist Device [Phase 2]
Phase 2 trial investigating serial infusions of allogeneic mesenchymal stem cells in cardiomyopathy patients with left ventricular assist de…
-
FDA approval · 2022-01-26FDA Approved: ISOSORBIDE MONONITRATE — Supplemental Application (Edenbridge Pharmaceuticals LLC.)
FDA approved a supplemental application for Edenbridge Pharmaceuticals' generic Isosorbide Mononitrate.
-
FDA label_change · 2022-01-12FDA Approved: TOPROL XL — Supplemental Application (Melinta Therapeutics, LLC)
FDA approved a supplemental application for TOPROL XL (metoprolol succinate) to update the labeling, submitted by Melinta Therapeutics, LLC.
-
FDA approval · 2021-12-21FDA Approved: CLOPIDOGREL BISULFATE — Supplemental Application (Dr.Reddy's Laboratories Limited)
FDA approved a supplemental application for clopidogrel bisulfate submitted by Dr. Reddy's Laboratories Limited. The action confirms approva…
-
CLINICAL_TRIALS trial_result · 2021-09-14Clinical Trial Update: Rituximab in Patients With Acute ST-elevation Myocardial Infarction Study [Phase 1, Phase 2]
Clinical trial update for Rituximab in acute ST-elevation myocardial infarction (Phase 1/2) completed.
-
CLINICAL_TRIALS trial_result · 2021-09-14Clinical Trial Update: Low Dose Interleukin-2 in Patients With Stable Ischaemic Heart Disease and Acute Coronary Syndromes [Phase 1, Phase 2]
A phase 1/2 trial evaluating low dose interleukin-2 in patients with ischemic heart disease, completed.
-
CLINICAL_TRIALS trial_result · 2021-05-24Clinical Trial Update: Autologous Bone Marrow Mononuclear Cells in the Combined Treatment of Coronary Heart Disease [NA]
Clinical trial update on autologous bone marrow mononuclear cells used with other treatments for ischemic heart disease; study completed wit…
-
CLINICAL_TRIALS trial_result · 2021-04-08Clinical Trial Update: Dobutamine Echocardiography In Patients With Ischemic Heart Failure Evaluated for Revascularization [NA]
Clinical trial update for dobutamine echocardiography in ischemic heart failure patients evaluated for revascularization; study completed wi…
-
FDA approval · 2021-03-05FDA Approved: PRAVASTATIN SODIUM — Supplemental Application (Accord Healthcare Inc.)
FDA approved a supplemental application for Accord Healthcare's generic pravastatin sodium, updating its regulatory status as an approved ge…
-
FDA approval · 2021-01-15FDA Approved: ATORVASTATIN CALCIUM — Supplemental Application (Mylan Pharmaceuticals Inc.)
FDA approved a supplemental application for atorvastatin calcium (generic atorvastatin) manufactured by Mylan Pharmaceuticals Inc.